Clinical Trial: Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma

U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT06884683) titled 'Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma' on March 14, 2023.

Brief Summary: Phase 2 single arm study that evaluated the addition of metformin to nivolumab in pre-treated metastatic renal cell carcinoma (mRCC) patients.

Primary aim: to investigate the efficacy of the combination of nivolumab+metformin in mRCC patients previously treated with VEGFR-TKI

Secondary aims:

* to assess the activity, safety and efficacy of the experimental combination

* to assess the quality of life of enrolled patients

Enrolled patients will received:

* nivolumab 240 mg e.v. every 14 day

* metformin 500 mg orally twice a day conti...